Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

@article{Kirschbaum2011PhaseIS,
  title={Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.},
  author={Mark H. Kirschbaum and Paul Frankel and Leslie L Popplewell and Jasmine M. Zain and Maria L. Delioukina and Vinod Pullarkat and Deron Matsuoka and Bernadette Pulone and Arnold J Rotter and Igor Espinoza-Delgado and Auayporn P. Nademanee and Stephen J. Forman and David Gandara and Edward Newman},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 9},
  pages={1198-203}
}
PURPOSE We performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients with relapsed/refractory indolent lymphoma. PATIENTS AND METHODS In this open label phase II study (NCT00253630), patients with relapsed/refractory follicular lymphoma (FL), marginal zone lymphoma (MZL… CONTINUE READING